All In Biotech

Drug Trial Radar · NCT00362895

A Bioequivalence Study of Tobradex AF

A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension

Last checked: Nov 19, 2026Latest source record: Mar 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 995 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

995

Actual

Start

Apr 2006

Primary completion

Aug 2006

Study completion Aug 2006

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Aug 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.

Conditions

  • Cataract

Interventions

  • Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspensionDrug

    One drop in the study eye, single dose

  • Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)Drug

    One drop in the study eye, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of dexamethasone in aqueous humor following a single topical ocular administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon for Trial Location(s)

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.